Medacta Group SA (MOVE) AI Stock Analysis

• Market Cap: $2.97B
• Dividend Yield: 0.45%
• Average Volume (3M): 12.13K
• Price to Earnings (P/E): 33.1
• Beta (1Y): 0.94
• Revenue Growth: 16.59%
• EPS Growth: 65.76%
• Country: CH
• Employees: 1,907
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 2.84
• Shares Outstanding: 20,000,000
• 10 Day Avg. Volume: 8,750
• 30 Day Avg. Volume: 12,134
• PEG Ratio: 0.58
• Price to Book (P/B): 5.97
• Price to Sales (P/S): 3.84
• P/FCF Ratio: 924.69
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 4.47
• Enterprise Value/Gross Profit: 6.60
• Enterprise Value/Ebitda: 16.03
• 1Y Price Target: $167.56
• Price Target Upside: 10.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: CHF163.00 ▲(7.38% Upside)

Medacta Group SA's overall stock score reflects strong financial performance and positive earnings call insights, highlighting robust revenue and profit growth. However, the valuation appears high, and technical indicators suggest a neutral trend. The company's ability to manage costs and maintain growth will be crucial in sustaining its performance.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Medacta's products and successful market expansion, supporting long-term business sustainability.

Profitability Improvements

Significant net profit growth reflects effective cost management and pricing strategies, enhancing Medacta's financial health and shareholder value.

Strategic Acquisition

The Parcus acquisition strengthens Medacta's product portfolio and market position, potentially driving future revenue and profit growth.

Negative Factors

High Capital Expenditures

High capital expenditures limit free cash flow, potentially constraining Medacta's ability to invest in new opportunities and maintain financial flexibility.

Gross Margin Decline

A slight decline in gross margin, though minor, could indicate challenges in maintaining cost efficiency, affecting long-term profitability.

EBITDA Margin Pressure

Expected reduction in EBITDA margin suggests potential cost pressures, which could hinder Medacta's ability to sustain high profitability levels.

Medacta Group SA Business Overview & Revenue Model

Company Description

Medacta Group SA is a global medical device company specializing in orthopedic products and solutions. Founded in 1999 and headquartered in Switzerland, Medacta focuses on innovative surgical solutions, particularly in the fields of knee and hip arthroplasty, spinal surgery, and sports medicine. The company is known for its advanced technologies, including patient-specific implants and minimally invasive surgical techniques, which aim to improve patient outcomes and enhance surgical efficiency.

How the Company Makes Money

Medacta generates revenue primarily through the sale of orthopedic implants and surgical instruments used in joint replacement and spinal surgeries. The company's core revenue streams include the sale of its proprietary products, which are distributed through a global network of direct sales representatives and independent distributors. Additionally, Medacta offers value-added services such as training and educational programs for surgeons and medical professionals, further enhancing its market presence. Key partnerships with hospitals and surgical centers, along with participation in various orthopedic and medical conferences, also contribute significantly to its earnings by expanding its customer base and promoting its innovative solutions.

Medacta Group SA Financial Statement Overview

Summary

Medacta Group SA exhibits strong financial health with impressive revenue growth and profitability improvements. The balance sheet is stable, with manageable leverage and improved equity returns. However, cash flow from operations is strong, though high capital expenditures limit free cash flow. Continued focus on optimizing capital expenditures could enhance liquidity and financial flexibility.

Income Statement

Medacta Group SA has shown strong revenue growth from 2023 to 2024, with a revenue growth rate of 15.61%. The gross profit margin remains robust at 67.6% for 2024, reflecting efficient cost management and product pricing. Net profit margin improved to 12.34%, indicating enhanced profitability. Both EBIT and EBITDA margins have increased to 15.38% and 27.18% respectively, showcasing strong operational performance. Overall, the income statement indicates healthy growth and profitability.

Balance Sheet

The company's balance sheet demonstrates solid equity growth, with a rise in stockholders' equity from 2023 to 2024. The debt-to-equity ratio remains stable at 0.64, suggesting manageable leverage. Return on equity improved to 19.2%, indicating efficient use of equity to generate profits. The equity ratio stands at 47.92%, reflecting a balanced capital structure. While leverage is within a comfortable range, continued monitoring is advised to maintain financial stability.

Cash Flow

Operating cash flow has increased significantly to 107.1M in 2024, reflecting strong cash generation capabilities. However, free cash flow remains low at 2.45M due to high capital expenditures, potentially impacting liquidity. The operating cash flow to net income ratio is robust at 1.47, indicating effective conversion of profits into cash. The free cash flow to net income ratio is weak at 0.03, suggesting limited cash availability for discretionary uses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	646.07M	590.58M	510.78M	437.12M	363.13M	302.49M
Gross Profit	436.82M	399.44M	347.85M	305.26M	261.25M	214.26M
EBITDA	179.99M	160.51M	119.64M	106.96M	97.81M	81.96M
Net Income	94.93M	72.89M	47.36M	46.25M	51.52M	37.09M
Balance Sheet
Total Assets	860.76M	792.18M	695.87M	584.49M	489.27M	441.94M
Cash, Cash Equivalents and Short-Term Investments	33.24M	31.59M	20.79M	32.26M	20.40M	48.07M
Total Debt	254.83M	241.21M	201.98M	170.25M	132.66M	150.00M
Total Liabilities	436.15M	412.51M	365.83M	309.83M	262.87M	277.22M
Stockholders Equity	424.61M	379.66M	330.04M	274.65M	226.40M	164.72M
Cash Flow
Free Cash Flow	27.06M	2.45M	-7.09M	10.35M	7.57M	32.31M
Operating Cash Flow	138.25M	107.14M	75.13M	73.51M	54.06M	59.59M
Investing Cash Flow	-109.25M	-98.87M	-80.61M	-65.11M	-52.04M	-34.19M
Financing Cash Flow	-14.19M	4.33M	-10.13M	3.44M	-31.21M	-6.03M

Medacta Group SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 151.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOVE, the sentiment is Positive. The current price of 151.8 is below the 20-day moving average (MA) of 151.99, above the 50-day MA of 149.01, and above the 200-day MA of 140.00, indicating a neutral trend. The MACD of 1.04 indicates Positive momentum. The RSI at 51.73 is Neutral, neither overbought nor oversold. The STOCH value of 33.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:MOVE.

Medacta Group SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STMN	72 Outperform	CHF14.65B	36.90	―	1.04%	4.49%	45.08%
MOVE	71 Outperform	$2.97B	33.09	23.83%	0.45%	16.59%	65.76%
YPSN	70 Outperform	CHF4.38B	22.58	27.15%	0.69%	27.63%	160.67%
TECN	62 Neutral	CHF1.80B	28.26	4.57%	2.24%	-9.34%	-37.50%
MED	62 Neutral	CHF1.06B	-1,989.80	―	―	7.29%	-112.70%
KURN	61 Neutral	CHF1.14B	―	-7.82%	―	104.01%	33.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Medacta Group SA Corporate Events

Medacta Group SA Reports Strong H1 2025 Results with 19.8% Revenue Growth

Medacta Group SA reported a significant increase in its adjusted EBITDA margin to 29.6% in the first half of 2025, with revenues reaching €344.1 million, a 19.8% rise in constant currency. The company’s growth was driven by innovations across all business lines, including the launch of new products like the NextAR Rod Optimizer and MyImplant for Hip, as well as the acquisition of Parcus Medical, which expanded its sports medicine portfolio. Medacta’s strategic initiatives and expansion efforts have positioned it for continued success, with notable revenue growth in key regions such as North America and Asia Pacific, and across all product lines, particularly in knee and extremities.